Epidemiology of Psoriasis and Psoriatic Arthritis

Cimmino, Marco A.

doi:10.4081/reumatismo.2007.1s.19

Cited by 21 publications

(21 citation statements)

References 27 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although Kubota et al . have reported that the prevalence of psoriasis in Japan is 0.34%, the international prevalences range from no cases in the Samoan Islands to 12% in Russian Kasach'ye …”

Section: Discussionmentioning

confidence: 97%

Epidemiological survey from 2009 to 2012 of psoriatic patients in Japanese Society for Psoriasis Research

Ito

Takahashi

Kawada

et al. 2017

The Journal of Dermatology

View full text Add to dashboard Cite

Since 1982, the Japanese Society for Psoriasis Research has conducted annual epidemiological surveys of patients with psoriasis. Kawada et al. have reported data for 1982-2001 and Takahashi et al. have reported data for 2002-2008. The present study evaluated 9290 psoriatic cases according to age and sex (2009-2012). The male : female ratio was 2.08:1 (6281 male patients [67.6%] to 3009 female patients [32.4%]). The most prevalent type was psoriasis vulgaris (85.6% of all cases), which was followed by psoriasis arthropathica (6.0%), psoriasis guttate acuta (3.2%), Zumbusch-type generalized pustular psoriasis (1.8%) and psoriasis erythroderma (1.5%). Psoriasis vulgaris was the most prevalent type for all ages, while psoriasis arthropathica and psoriasis guttate acuta were most prevalent among patients aged less than 65 years. The present survey detected an increased number of cases with comorbid diabetes and/or arthritis symptoms compared with the previous surveys. We found that treatments frequently involved topical corticosteroids (89.7% of cases) and vitamin D ointments (78.0% of cases), with a notable increase in the use of vitamin D ointments. Systemic treatments were used in 33.3% of cases, including cyclosporin (33.6%), etretinate (19.5%), methotrexate (8.6%), infliximab (11.4%), adalimumab (10.9%) and ustekinumab (6.2%). Phototherapy was used in 30.9% of cases. Although psoralen plus ultraviolet A therapy was the predominant phototherapy during previous studies, the present survey revealed that narrowband ultraviolet B therapy was used in 84.5% of phototherapy-treated cases. Thus, the present survey revealed major changes in treatment trends.

show abstract

Section: Discussionmentioning

confidence: 97%

Epidemiological survey from 2009 to 2012 of psoriatic patients in Japanese Society for Psoriasis Research

Ito

Takahashi

Kawada

et al. 2017

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…The condition is thought to be caused by an immune system dysfunction, with increased infiltration of immune cells such as lymphocytes (T cells) and hyperproliferation of skin cells . The global average prevalence of psoriasis was estimated as 3–4% . Among all seven types of psoriasis, vulgaris (plaque) is the most common, presenting in 90% of people with psoriasis .…”

Section: Introductionmentioning

confidence: 99%

Oral Chinese herbal medicine combined with pharmacotherapy for psoriasis vulgaris: a systematic review

Zhang

Parker

et al. 2014

Int J Dermatology

View full text Add to dashboard Cite

Clinically, oral Chinese herbal medicine (CHM) is widely used in the treatment of psoriasis. This review evaluates the effects of oral CHM in combination with pharmacotherapy for psoriasis vulgaris. The Cochrane Library, PubMed, Embase, CINAHL, CNKI, and CQVIP were searched from their inceptions to November 2012. Randomized controlled trials (RCTs) investigating CHM plus pharmacotherapy compared to pharmacotherapy were included. Data were analyzed using Review Manager 5.1.0. Seventeen RCTs were included, conducted in China, and employed a diversity of both herbal medicines and pharmacotherapies. When the meta-analyses were restricted to studies that used a well-known pharmacotherapy as the comparator with 60% or greater clinical improvement in psoriasis as the outcome, five studies used oral acitretin, one used topical calcipotriol, and one used topical clobetasol propionate as control interventions. At the end of treatment, there was a benefit for the pooled result of the five studies that compared CHM plus acitretin with acitretin alone and no serious adverse events were reported. However, none of these studies was blind, so there is considerable risk of bias in this result. In addition, there was inadequate reporting of longer-term results, so it remains unclear whether the reported effect could be maintained or whether the prolonged use of the CHM in conjunction with acitretin would be safe. The main plants used in these studies, Rehmannia glutinosa root, Salvia miltiorrhiza root, and Lithospermum erythrorhizon root, have shown anti-inflammatory and/or antiproliferative effects in experimental studies. These actions may at least partially explain the observed results.

show abstract

“…TNF-inhibitor therapy offers added value to patients with psoriasis because it is estimated that 11% of patients with psoriasis (range 1-39%, depending on a variety of diagnosis criteria and/or different stages of the disease) also have PsA, according to population-based research. 51 Guidelines for management of psoriasis and PsA, and reviews of the value of screening and monitoring tests when using biologic agents for psoriasis were recently published. [52][53][54] Just as the NNT is a helpful tool in clinical decision-making, recommendations from these guidelines are useful for the management of psoriasis with biologic therapy.…”

Section: Discussionmentioning

confidence: 99%